Pink Sheet – Accelerated Approval Is For Patients, Not Sponsors – US FDA’s Pazdur
The US Food & Drug Administration oncology drug review team is getting a lot of attention for cleaning up accelerate approval indications after confirmatory studies fail. But the agency is also drawing some lines in the sand when it comes to granting Accelerated Approval in the first place. In 2021 – in the midst of…